J B Chemicals & Pharmaceuticals Ltd
JBCHEPHARMJ B Chemicals & Pharmaceuticals Ltd's price has outrun its earnings. +45.6% in a year against EPS +4.3% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +45.6% in a year while annual EPS moved +4.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (34 weeks in) while the P/E sits at the 99th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −30.8% year on year, and 125% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
J B Chemicals & Pharmaceuticals Ltd trades at ₹2,409, in a confirmed uptrend and 34 weeks into that stage. That is +18.9% against its own 200-day average. It sits at 97% of a 52-week range of ₹1,668 to ₹2,436. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 34 of stage 2, confirmed. At ₹2,409 it trades +18.9% versus its 200-day average and sits at 97% of its 52-week range (₹1,668–₹2,436).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +1,854% while the NIFTY 500 moved +280% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 99th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
J B Chemicals & Pharmaceuticals Ltd trades at 53.8× P/E, about the priciest it has ever traded. Its long-run median P/E is 28.0×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 53.8× is about the priciest it has ever traded, against a long-run median of 28.0× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +4.3% against a +45.6% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +20.6%/yr price move, ~+9.1%/yr came from earnings growth and ~+11.5 pp from the multiple (expanding); over 10y, of the +33.8%/yr price move, ~+23.2%/yr came from earnings growth and ~+10.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
J B Chemicals & Pharmaceuticals Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 23.9% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.9% | +9.6% | +15.2% | +13.1% |
| Profit | +7.4% | +20.0% | +9.6% | +15.8% |
| EPS | +4.3% | +18.6% | +8.8% | +16.5% |
| Share price | +45.6% | +23.3% | +20.6% | +33.8% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
48.9/100 — rank 22 of 43 in Pharma - Formulators · 96% evidence confidence
J B Chemicals & Pharmaceuticals Ltd scores 48.9 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 22. Price leads the evidence: RS versus the benchmark is 23.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 11.6 + 20.6 + 3.7 + 13 = 48.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
J B Chemicals & Pharmaceuticals Ltd reported ₹904 Cr of revenue in the Mar 26 quarter, −4.7% year on year. Over 10 years it has compounded at 13.1% a year. The last full year, FY26, came in at ₹4,148 Cr. The last four reported quarters add to ₹4,148 Cr.
J B Chemicals & Pharmaceuticals Ltd reported ₹904 Cr of revenue in the Mar 26 quarter, −4.7% year on year. Over 10 years it has compounded at 13.1% a year. The last full year, FY26, came in at ₹4,148 Cr. The last four reported quarters add to ₹4,148 Cr.
FY26 revenue came in at ₹4,148 Cr (+5.9% on the year), capping 10 years at 13.1% compound. The latest quarter (Mar 26) printed ₹904 Cr, −4.7% year on year.
Pace check: the last four quarters averaged +5.8% growth against the decade's 13.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +5.9% over the last 4 quarters against +9.1%/yr over the last 8 — rolling over; TTM profit +7.4% vs +13.2%/yr — rolling over.
→ Revenue slipped — did margins hold as it scaled? Next: 22.0% this quarter (−2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
J B Chemicals & Pharmaceuticals Ltd's operating margin is 22.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 14.0% to 27.0%. The current quarter sits inside that band.
J B Chemicals & Pharmaceuticals Ltd's operating margin is 22.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 14.0% to 27.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 22.0%, −2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 14.0%–27.0%, and FY26's 27.0% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −1.6 pp year on year while gross margin went +3.5 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins slipped — did that reach the bottom line? Next: profit −30.8% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
J B Chemicals & Pharmaceuticals Ltd earned ₹101 Cr of net profit in the Mar 26 quarter, −30.8% year on year. Full-year FY26 profit was ₹709 Cr. The 10-year compound rate is 15.8%. That is 11.2% of the quarter's revenue. The same quarter a year earlier earned ₹146 Cr.
J B Chemicals & Pharmaceuticals Ltd earned ₹101 Cr of net profit in the Mar 26 quarter, −30.8% year on year. Full-year FY26 profit was ₹709 Cr. The 10-year compound rate is 15.8%. That is 11.2% of the quarter's revenue. The same quarter a year earlier earned ₹146 Cr.
Mar 26 profit was ₹101 Cr, −30.8% year on year. On the full year, FY26 printed ₹709 Cr (+7.4%), and the 10-year compound rate is 15.8%.
🚨 Why profit moved: revenue contributed −4.7% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +6.1% vs revenue +5.8%. Profit and revenue are moving roughly in step.
→ Profit rose — but did the cash follow? Next: 125% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 125% of J B Chemicals & Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹704 Cr of operating cash against ₹709 Cr of profit. After ₹110 Cr of capital spending, ₹594 Cr was left as free cash.
FY26: operating cash of ₹704 Cr against reported profit of ₹709 Cr, leaving free cash of ₹594 Cr after ₹110 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 125% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 125%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
→ So follow the cash to where it goes. Next: a 151-day cycle and ₹494 Cr of building.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
J B Chemicals & Pharmaceuticals Ltd's cash conversion cycle runs 151 days in FY26, down from 153 days in FY21. Capital spending ran ₹494 Cr over the last 3 years. At FY26 sales of ₹4,148 Cr each day of that cycle holds about ₹11.4 Cr, so roughly ₹1,716 Cr sits inside the business at any moment.
FY26: debtors at 69 days, inventory at 192 days — roughly 6.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 151 days, tighter than FY21's 153.
The full loop: cash goes out to suppliers and production on day 0; stock waits 192 days to sell; customers pay about 69 days after that; and suppliers themselves are paid at 110 days — netting out to the 151-day cycle.
In money terms: at FY26 sales of ₹4,148 Cr, each day of the cycle holds about ₹11.4 Cr — so the 151-day loop keeps roughly ₹1,716 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹494 Cr over the last 3 fiscal years against ₹491 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹74.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 25% and the ROIC − WACC spread is +10.2 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
J B Chemicals & Pharmaceuticals Ltd earns a ROCE of 25% in FY26. That is up from a trough of 11% in FY18. Return on invested capital clears the cost of that capital by +10.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 17.1% net margin on 0.84× asset turns.
FY26 ROCE is 25%, recovered from a FY18 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 17.1% net margin × 0.84× asset turns × 1.19× balance-sheet leverage ≈ 17.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 22.2% − 12.0% = a +10.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
J B Chemicals & Pharmaceuticals Ltd carries total debt of ₹4.0 Cr against shareholder equity of ₹4,159 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.03 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹4.0 Cr against shareholder equity of ₹4,159 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.03 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 5.0 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 5.0 points of J B Chemicals & Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 48.8% of the company. Foreign institutions moved +4.2 points over the same window, to 16.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −5.0 points over 8 quarters to 48.8%; Foreign institutions: +4.2 points over 8 quarters to 16.3%; Domestic institutions: +3.8 points over 8 quarters to 21.4%.
🚨 Why the register moved: promoters drove it (−5.0 points), absorbed on the other side by foreign institutions (+4.2 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
J B Chemicals & Pharmaceuticals Ltd: the Z-score reads 23.55. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 23.55 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 23.55.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| J B Chemicals & Pharmaceuticals Ltd this page | 53.8× | ₹38,677 Cr | Topping out | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is J B Chemicals & Pharmaceuticals Ltd's share price today?
J B Chemicals & Pharmaceuticals Ltd trades at ₹2,409, +45.6% over the past year. The company is valued at ₹38,677 Cr. The stock sits at 97% of its 52-week range of ₹1,668–₹2,436, +18.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 34 weeks in. — as of 24 July 2026.
What were J B Chemicals & Pharmaceuticals Ltd's latest quarterly results?
J B Chemicals & Pharmaceuticals Ltd reported revenue of ₹904 Cr and net profit of ₹101 Cr for the Mar 26 quarter. Revenue fell 4.7% and profit fell 30.8% year on year. Earnings per share were ₹6.31. The operating margin was 22.0%, 2.0 pp lower than a year earlier. — as of 24 July 2026.
What is J B Chemicals & Pharmaceuticals Ltd's revenue?
J B Chemicals & Pharmaceuticals Ltd reported revenue of ₹904 Cr in the Mar 26 quarter, −4.7% year on year. For the full FY26 fiscal year, revenue was ₹4,148 Cr (+5.9%). Over the last 10 years revenue compounded at 13.1% a year. — as of 24 July 2026.
What is J B Chemicals & Pharmaceuticals Ltd's profit?
J B Chemicals & Pharmaceuticals Ltd earned ₹101 Cr of net profit in the Mar 26 quarter, −30.8% year on year. Full-year FY26 profit was ₹709 Cr. The operating margin ran 22.0% in the latest quarter. — as of 24 July 2026.
What is J B Chemicals & Pharmaceuticals Ltd's market cap?
J B Chemicals & Pharmaceuticals Ltd's market capitalisation is ₹38,677 Cr at a share price of ₹2,409. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is J B Chemicals & Pharmaceuticals Ltd's P/E ratio?
J B Chemicals & Pharmaceuticals Ltd trades at a P/E of 53.8×, at the 99th percentile of its own 10-year range, against a long-run median of 28.0×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does J B Chemicals & Pharmaceuticals Ltd pay a dividend?
Yes — J B Chemicals & Pharmaceuticals Ltd's dividend payout was 50% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is J B Chemicals & Pharmaceuticals Ltd overvalued?
On its own history, J B Chemicals & Pharmaceuticals Ltd looks expensive against its own history: its P/E of 53.8× sits at the 99th percentile of its 10-year range (long-run median 28.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is J B Chemicals & Pharmaceuticals Ltd growing?
Not right now — J B Chemicals & Pharmaceuticals Ltd's latest numbers are shrinking: latest-quarter revenue −4.7% year on year, profit −30.8%, and the margin −2.0 pp at 22.0%. The 10-year compound rates are 13.1% (revenue) and 15.8% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is J B Chemicals & Pharmaceuticals Ltd performing?
J B Chemicals & Pharmaceuticals Ltd is in a confirmed uptrend, 34 weeks in. Its latest quarter's revenue fell 4.7% and profit fell 30.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 9 weeks. — as of 24 July 2026.
What stage is J B Chemicals & Pharmaceuticals Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 23.9% and holding. The read comes from the last 12 quarters of growth (revenue growth +5.9% latest, profit growth +7.4% latest, eps growth +6.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is J B Chemicals & Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 34 of stage 2), trading +18.9% versus its 200-day average and at 97% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is J B Chemicals & Pharmaceuticals Ltd beating the market?
On recent form, yes — J B Chemicals & Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +1,854% against the NIFTY 500's +280% — ahead of the index over the full window. — as of 24 July 2026.
Will J B Chemicals & Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for J B Chemicals & Pharmaceuticals Ltd. What it measures instead: the share price is ₹2,409, the price is in a confirmed uptrend 34 weeks in. Its P/E of 53.8× sits at the 99th percentile of its own 10-year range. — as of 24 July 2026.
Who owns J B Chemicals & Pharmaceuticals Ltd?
Promoters hold 48.8% of J B Chemicals & Pharmaceuticals Ltd, foreign institutions 16.3%, domestic institutions 21.4% and the public 13.5% (latest quarter). The biggest move on the register over the last two years: Promoters cut 5.0 points over 8 quarters. — as of 24 July 2026.
Does J B Chemicals & Pharmaceuticals Ltd have too much debt?
No — J B Chemicals & Pharmaceuticals Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹4.0 Cr against equity of ₹4,159 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is J B Chemicals & Pharmaceuticals Ltd's capex?
J B Chemicals & Pharmaceuticals Ltd spent ₹494 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹110 Cr, with ₹74.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is J B Chemicals & Pharmaceuticals Ltd's cash flow?
J B Chemicals & Pharmaceuticals Ltd generated ₹704 Cr of operating cash flow in FY26 and ₹594 Cr of free cash flow after ₹110 Cr of capital spending. Reported profit that year was ₹709 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is J B Chemicals & Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 125% of J B Chemicals & Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹704 Cr against reported profit of ₹709 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is J B Chemicals & Pharmaceuticals Ltd?
On the balance sheet, the Z-score reads 23.55 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is J B Chemicals & Pharmaceuticals Ltd in its business cycle?
J B Chemicals & Pharmaceuticals Ltd's FY26 operating margin was 27.0%, against a 13-year band of 14.0%–27.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 22.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the J B Chemicals & Pharmaceuticals Ltd story?
The sharpest disagreement: the price moved +45.6% in a year while annual EPS moved +4.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is J B Chemicals & Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: J B Chemicals & Pharmaceuticals Ltd's price has outrun its earnings. +45.6% in a year against EPS +4.3% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.